



CREAPHARM OPENS U.S. LOCATION FOR EXPANSION OF CYTOTOXIC AND HIGH POTENCY CLINICAL TRIAL MATERIAL SUPPLY IN NORTH AMERICA

October 7, 2009 - Creapharm Europe is pleased to announce the establishment of a U.S. subsidiary, Creapharm-MP5, Inc. Creapharm Europe, through its subsidiaries Creapharm and MP5 is a leading contract manufacturer of cytotoxic and other high-potency drugs in addition to clinical supply services headquartered in Europe. Accompanying this announcement is the appointment of Matthew Maupin as Vice President of Business Development-North America.

The launch of Creapharm Europe's U.S. subsidiary and the hiring of Mr. Maupin is the first critical step towards providing superior services for pharmaceutical and biotech companies in North America. In his most recent position, Mr. Maupin was the Vice President of Business Development for a U.S. CMO (contract manufacturing organization). He has previously held leadership positions in Quality and Operations in addition to owning a research reagent business focused on RNAi (RNA interference). Matt's initial efforts will concentrate on promoting MP5's services in the U.S. and Canada with particular focus on the oncology market. In addition, he will emphasize Creapharm's clinical supply offerings, which provide an advantageous benefit to the customer base of MP5. Creapharm-MP5 is poised to become a leader in contract manufacturing and clinical supply services for the North American market.

About MP5:

MP5 is a contract manufacturer of clinical trial materials focused on formulation, aseptic filling, and lyophilization of cytotoxics and other high potency drugs as well as biologics. MP5 has produced hundreds of batches since its inception over ten years ago and is compliant with U.S. and EU (EMEA) GMPs. MP5 is registered by the French Health Agency (AFSSAPS) for the manufacture of clinical trial materials according to the EU-GMP Annex 13 under authorization number M02/150. MP5 is committed to quality and has Qualified Persons (QPs) on staff to release product for use in the EU. MP5 uses proprietary isolator technology to ensure the highest level of sterility assurance as well as protect technicians in the manufacturing process.

About Creapharm:

Creapharm is a leading clinical supply company in Europe. Creapharm offers Phase I-IV clinical manufacturing, packaging and labeling as well as clinical inventory management, and cold chain distribution with a large network of worldwide depots to meet client's diverse clinical trial needs. Creapharm has produced over 6,000 batches since its inception.

For more information, please contact:

CREAPHARM-MP5, INC.

Matt Maupin

VP, Business Development – North America

Tel.: (508) 536-6000

E-mail: maupin@creapharm.com

Web: www.creapharm.com / www.mp5services.com